Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Precision Biosciences (DTIL) EBT (2018 - 2025)

Precision Biosciences (DTIL) has disclosed EBT for 8 consecutive years, with -$20.0 million as the latest value for Q3 2025.

  • On a quarterly basis, EBT fell 1.18% to -$20.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$86.0 million, a 676.32% decrease, with the full-year FY2024 number at -$21.2 million, up 44.67% from a year prior.
  • EBT was -$20.0 million for Q3 2025 at Precision Biosciences, up from -$21.1 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $25.4 million in Q2 2024 to a low of -$30.7 million in Q4 2021.
  • A 5-year average of -$11.2 million and a median of -$13.9 million in 2022 define the central range for EBT.
  • Peak YoY movement for EBT: surged 1564.8% in 2024, then plummeted 582.47% in 2025.
  • Precision Biosciences' EBT stood at -$30.7 million in 2021, then skyrocketed by 161.93% to $19.0 million in 2022, then crashed by 171.72% to -$13.6 million in 2023, then tumbled by 74.05% to -$23.7 million in 2024, then increased by 15.76% to -$20.0 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's EBT are -$20.0 million (Q3 2025), -$21.1 million (Q2 2025), and -$21.1 million (Q1 2025).